Abrégé

The present invention relates to a pharmaceutical composition comprising crisdesalazine or a salt thereof, which has improved stability by reducing the content of related substances of crisdesalazine, and has an increased dissolution rate by improving the intrinsic solubility thereof. The composition of the present invention secures stability and bioavailability, and thus is more effective in treating neurodegenerative diseases (Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, epilepsy accompanied by free radical neurotoxicity, cerebral trauma, spinal injury, and the like), inflammatory diseases (gastritis, colitis, pancreatitis, arthritis, diabetic inflammation, inflammatory bowel disease, nephritis, hepatitis, arteriosclerosis inflammation, and the like), stress disorders (anxiety disorder, depression, and the like), and the like.

Classes IPC  ?

• A61K 9/20 - Pilules, pastilles ou comprimés
• A61K 31/606 - Acide salicyliqueSes dérivés ayant des groupes amino
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
• A61P 25/22 - Anxiolytiques
• A61P 25/24 - Antidépresseurs

Abrégé

2-hydroxy-5-[2-(4-(trifluoromethylphenyl)ethylamino)]benzoic acid crystal forms and a preparation method therefor are proposed. Crystal form I is a monoclinic crystal system, which has a Pc space group and can be obtained by slow cooling, evaporating the solvent at a constant temperature, evaporating the solvent at an increased temperature, or adding an anti-solvent. Crystal form II is a triclinic crystal system, which has a P1 space group and can be obtained by rapid cooling or freeze-drying. According to the method, the process is simple, costs are low, and the yield exceeds 90%; and the crystal forms of the crystal forms I and II have high purity, the crystal shapes thereof are intact, and have excellent fluidity, facilitating preparation, particularly the preparation of a pharmaceutical preparation for preventing and/or treating degenerative diseases of the central nervous system. Furthermore, the two crystal forms have a better apparent solubility than that of raw materials.

Classes IPC  ?

• C07C 229/64 - Composés contenant des groupes amino et carboxyle liés au même squelette carboné ayant des groupes amino et carboxyle liés à des atomes de carbone de cycles aromatiques à six chaînons du même squelette carboné avec des groupes amino et carboxyle liés à des atomes de carbone du même cycle aromatique à six chaînons non condensé le squelette carboné étant substitué de plus par des atomes d'oxygène liés par des liaisons simples

Abrégé

A method for preparing 2-hydroxy-5-[2-(4-(trifluoromethylphenyl)ethylamino)]benzoic acid is proposed. The method may include protection, condensation, and hydrolysis. By means of the screening of a hydroxyl protecting reagent for a starting material, for example, 2-(4-trifluoromethyl)phenethylalcohol and the optimization of other process parameters, the contents of meta-isomer impurities and disubstituted impurities in a target product are effectively controlled. Accordingly, the quality of the product is significantly improved, the reaction yield is also greatly improved, and the improved product quality can satisfy related requirements of preparation research.

Classes IPC  ?

• C07C 227/18 - Préparation de composés contenant des groupes amino et carboxyle liés au même squelette carboné à partir de composés contenant déjà des groupes amino et carboxyle ou leurs dérivés par des réactions impliquant des groupes amino ou carboxyle, p. ex. hydrolyse d'esters ou d'amides, par formation d'halogénures, de sels ou d'esters
• C07C 303/28 - Préparation d'esters ou d'amides d'acides sulfuriquesPréparation d'acides sulfoniques ou de leurs esters, halogénures, anhydrides ou amides d'esters d'acides sulfoniques par réaction de composés hydroxy avec des acides sulfoniques ou leurs dérivés

Abrégé

The present invention relates to lipid nanoparticles for the delivery of proteins and, specifically, to lipid nanoparticles for the intracellular or in vivo delivery of various medicinal proteins such as therapeutic proteins or enzymes for enzyme replacement therapy (ERT). The present invention can be advantageously used for the treatment and prevention of various diseases, including lysosomal storage disorders, by stably and effectively delivering various proteins such as therapeutic proteins or ERT enzymes into cells through lipid nanoparticles.

Classes IPC  ?

• A61K 9/51 - Nanocapsules
• A61K 38/00 - Préparations médicinales contenant des peptides
• A61K 38/43 - EnzymesProenzymesLeurs dérivés

Abrégé

The present invention relates to pharmaceutical compositions and methods for treating ischemic stroke in humans, using a tetrafluorobenzyl derivative of formula (I) or a pharmaceutically acceptable salt thereof conjointly with a thrombolytic drug, endovascular thrombectomy, or both (e.g., endovascular thrombectomy and a thrombolytic drug). Administration of a tetrafluorobenzyl derivative of formula (I) or its pharmaceutically acceptable salt can reduce reperfusion injury and other adverse events in patients conjointly receiving a thrombolytic drug, endovascular thrombectomy, or endovascular thrombectomy with a thrombolytic drug.

Classes IPC  ?

• A61K 31/196 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino le groupe amino étant lié directement à un cycle, p. ex. acide anthranilique, acide méfénamique, diclofénac, chlorambucil
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 7/02 - Agents antithrombotiquesAnticoagulantsAnti-agrégants plaquettaires
• A61K 38/48 - Hydrolases (3) agissant sur des liaisons peptidiques (3.4)
• A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale

Abrégé

The present invention relates to an ophthalmic liquid composition comprising: a therapeutically effective amount of aflibercept; a buffer containing sodium acetate or histidine; a sugar including sucrose, trehalose or a combination thereof; and a surfactant that is polysorbate or poloxamer, and a composition for stabilizing aflibercept. The ophthalmic liquid composition of the present invention is characterized by the excellent effect of imparting stability against stresses upon agitation, repeated freezing and thawing, ultraviolet (UV) exposure, and storage at a high temperature.

Classes IPC  ?

• A61K 9/08 - Solutions
• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
• A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
• A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
• A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères

Abrégé

A salfaprodil freeze-dried powder injection, and a preparation method thereof and the use thereof are proposed. The preparation method may include adding salfaprodil into water for injection, filtering after the salfaprodil is completely dissolved, and adjusting pH of filtrate with an alkaline substance water solution. The method may also include adding the injection water to achieve a constant volume, filling with an inert gas for protection, and performing sterilization and filtration to obtain a salfaprodil solution, which is then freeze-dried to obtain the -salfaprodil freeze-dried powder injection.

Classes IPC  ?

• A61K 31/606 - Acide salicyliqueSes dérivés ayant des groupes amino
• A61K 9/19 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres lyophilisées
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier

Abrégé

The present invention relates to pharmaceutical compositions and methods useful for treating pulmonary disorders, including asthma, chronic obstructive pulmonary disease (COPD), asthma-COPD overlap syndrome (ACOD), or any other respiratory diseases comprising 2-hydroxybenzoic acid derivatives of the formula (I) or a pharmaceutically acceptable salt thereof. Administration of a 2-hydroxybenzoic acid derivative of formula (I) significantly alleviates airway tissue damage and inflammation in animal models of asthma and COPD.

Classes IPC  ?

• A61K 31/196 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino le groupe amino étant lié directement à un cycle, p. ex. acide anthranilique, acide méfénamique, diclofénac, chlorambucil
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire

Abrégé

The present invention relates to pharmaceutical compositions and methods useful for treating pulmonary disorders, including asthma, chronic obstructive pulmonary disease (COPD), asthma-COPD overlap syndrome (ACOD), or any other respiratory diseases comprising 2-hydroxybenzoic acid derivatives of the formula (I) or a pharmaceutically acceptable salt thereof. Administration of a 2-hydroxybenzoic acid derivative of formula (I) significantly alleviates airway tissue damage and inflammation in animal models of asthma and COPD.

Classes IPC  ?

• A61K 31/245 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques ayant un noyau aromatique lié au groupe carboxyle ayant un groupe amino ou nitro du type acide aminobenzoïque, p. ex. procaïne, novocaïne
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 11/06 - Antiasthmatiques

Produits et services

Cosmetics; perfumes; beauty masks; toiletry preparations; food flavorings [essential oils]; essential oils; laundry preparations; polishing preparations; cleaning, polishing, scouring and abrasive preparations; deodorants for human beings or for animals; air fragrancing preparations; incense; adhesives for cosmetic purposes; adhesives for affixing false hair; cleaning preparations; shampoos; cleansers for intimate personal hygiene purposes, non medicated; mouthwashes, not for medical purposes; cosmetics for animals; pre-moistened cleansing tissues.

Abrégé

The present invention relates to a composition comprising: a 5-benzyl aminosalicylic acid compound in chemical formula I or cosmetically acceptable salts thereof; and a cosmetically acceptable excipient suitable for local administration. The composition comprising the 5-benzyl aminosalicylic acid compound in chemical formula I or cosmetically acceptable salts thereof can be used for reducing or alleviating human skin aging by means of antioxidant, anti-inflammatory and whitening actions on the skin.

Classes IPC  ?

• A61K 8/44 - Acides aminocarboxyliques ou leurs dérivés, p. ex. acides aminocarboxyliques contenant du soufreLeurs sels, esters ou dérivés N-acylés
• A61K 8/67 - Vitamines
• A61K 8/60 - SucresLeurs dérivés
• A61K 8/9789 - Magnoliopsida [dicotylédones]
• A61K 8/34 - Alcools
• A61Q 19/02 - Préparations pour les soins de la peau pour décolorer ou blanchir la peau chimiquement
• A61Q 19/08 - Préparations contre le vieillissement
• A61K 8/11 - Compositions encapsulées
• A61K 8/02 - Cosmétiques ou préparations similaires pour la toilette caractérisés par une forme physique particulière

Abrégé

The present disclosure relates to pharmaceutical compositions for treating cognitive decline in companion animals, comprising a 5-benzylaminosalicylic acid compound of formula (I), or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient, e.g., suitable for oral administration. Compositions comprising the 5-benzylamino salicylic acid compound of formula (I), or a pharmaceutically acceptable salt thereof can be used to treat progressive cognitive disorder in neurological diseases including cognitive dysfunction syndrome (CDS), dysthymia, involutive depression, and confusional syndrome in aging companion animals.

Classes IPC  ?

• A61K 31/196 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino le groupe amino étant lié directement à un cycle, p. ex. acide anthranilique, acide méfénamique, diclofénac, chlorambucil
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/48 - Préparations en capsules, p. ex. de gélatine, de chocolat

Produits et services

Cosmetics; perfumes; beauty masks; non-medicated toiletry preparations; food flavoring, being essential oils; essential oils; laundry preparations, namely, laundry detergent, laundry bleach, laundry soap, laundry starch and laundry glaze; polishing preparations; cleaning, polishing, scouring and abrasive preparations; deodorants for human beings or for animals; air fragrancing preparations; incense; adhesives for cosmetic purposes; adhesives for affixing false hair; cleaning preparations; shampoos; cleansers for intimate personal hygiene purposes, non medicated; mouthwashes, not for medical purposes; cosmetics for animals; pre-moistened cleansing tissues, namely, pre-moistened cosmetic tissues

Abrégé

The present invention relates to the technical field of pharmaceutical crystal forms, and specifically relates to 2-hydroxy-5-[2-(4-(trifluoromethylphenyl)ethylamino)]benzoic acid crystal forms and a preparation method therefor. Crystal form I is a monoclinic crystal system, which has a Pc space group and can be obtained by means of crystallization methods of slow cooling, evaporating a solvent at a constant temperature, evaporating the solvent at an increased temperature, or adding an anti-solvent. Crystal form II is a triclinic crystal system, which has a P1 space group and can be obtained by crystallization methods such as rapid cooling or freeze-drying. The advantages of the two crystal forms and the preparation method therefor of the present invention are as follows: 1) the process is simple, costs are low, and the yield exceeds 90%; and 2) the crystal forms of the crystal forms I and II have high purity, the crystal shapes thereof are intact, and have excellent fluidity, facilitating preparation, particularly the preparation of a pharmaceutical preparation for preventing and/or treating degenerative diseases of the central nervous system; in addition, the two crystal forms have a better apparent solubility than that of raw materials.

Classes IPC  ?

• C07C 229/64 - Composés contenant des groupes amino et carboxyle liés au même squelette carboné ayant des groupes amino et carboxyle liés à des atomes de carbone de cycles aromatiques à six chaînons du même squelette carboné avec des groupes amino et carboxyle liés à des atomes de carbone du même cycle aromatique à six chaînons non condensé le squelette carboné étant substitué de plus par des atomes d'oxygène liés par des liaisons simples
• C07C 227/42 - Cristallisation

Abrégé

The present invention relates to the technical field of drug synthesis methods, and relates to a method for preparing 2-hydroxy-5-[2-(4-(trifluoromethylphenyl)ethylamino)]benzoic acid. The method comprises steps such as protection, condensation, and hydrolysis. By means of the screening of a hydroxyl protecting reagent for a starting material, i.e., 2-(4-trifluoromethyl)phenethylalcohol and the optimization of other process parameters, the contents of meta-isomer impurities and disubstituted impurities in a target product are effectively controlled, such that the quality of the product is significantly improved, the reaction yield is also greatly improved, and the improved product quality can satisfy related requirements of preparation research.

Classes IPC  ?

• C07C 227/18 - Préparation de composés contenant des groupes amino et carboxyle liés au même squelette carboné à partir de composés contenant déjà des groupes amino et carboxyle ou leurs dérivés par des réactions impliquant des groupes amino ou carboxyle, p. ex. hydrolyse d'esters ou d'amides, par formation d'halogénures, de sels ou d'esters
• C07C 229/64 - Composés contenant des groupes amino et carboxyle liés au même squelette carboné ayant des groupes amino et carboxyle liés à des atomes de carbone de cycles aromatiques à six chaînons du même squelette carboné avec des groupes amino et carboxyle liés à des atomes de carbone du même cycle aromatique à six chaînons non condensé le squelette carboné étant substitué de plus par des atomes d'oxygène liés par des liaisons simples

Abrégé

The present invention relates to the technical field of drug synthesis methods, and relates to a method for preparing 2-hydroxy-5-[2-(4-(trifluoromethylphenyl)ethylamino)]benzoic acid. The method comprises steps such as protection, condensation, and hydrolysis. By means of the screening of a hydroxyl protecting reagent for a starting material, i.e., 2-(4-trifluoromethyl)phenethylalcohol and the optimization of other process parameters, the contents of meta-isomer impurities and disubstituted impurities in a target product are effectively controlled, such that the quality of the product is significantly improved, the reaction yield is also greatly improved, and the improved product quality can satisfy related requirements of preparation research.

Classes IPC  ?

• C07C 227/18 - Préparation de composés contenant des groupes amino et carboxyle liés au même squelette carboné à partir de composés contenant déjà des groupes amino et carboxyle ou leurs dérivés par des réactions impliquant des groupes amino ou carboxyle, p. ex. hydrolyse d'esters ou d'amides, par formation d'halogénures, de sels ou d'esters
• C07C 229/64 - Composés contenant des groupes amino et carboxyle liés au même squelette carboné ayant des groupes amino et carboxyle liés à des atomes de carbone de cycles aromatiques à six chaînons du même squelette carboné avec des groupes amino et carboxyle liés à des atomes de carbone du même cycle aromatique à six chaînons non condensé le squelette carboné étant substitué de plus par des atomes d'oxygène liés par des liaisons simples

Abrégé

The present invention relates to the technical field of pharmaceutical crystal forms, and specifically relates to 2-hydroxy-5-[2-(4-(trifluoromethylphenyl)ethylamino)]benzoic acid crystal forms and a preparation method therefor. Crystal form I is a monoclinic crystal system, which has a Pc space group and can be obtained by means of crystallization methods of slow cooling, evaporating a solvent at a constant temperature, evaporating the solvent at an increased temperature, or adding an anti-solvent. Crystal form II is a triclinic crystal system, which has a P1 space group and can be obtained by crystallization methods such as rapid cooling or freeze-drying. The advantages of the two crystal forms and the preparation method therefor of the present invention are as follows: 1) the process is simple, costs are low, and the yield exceeds 90%; and 2) the crystal forms of the crystal forms I and II have high purity, the crystal shapes thereof are intact, and have excellent fluidity, facilitating preparation, particularly the preparation of a pharmaceutical preparation for preventing and/or treating degenerative diseases of the central nervous system; in addition, the two crystal forms have a better apparent solubility than that of raw materials.

Classes IPC  ?

• C07C 229/64 - Composés contenant des groupes amino et carboxyle liés au même squelette carboné ayant des groupes amino et carboxyle liés à des atomes de carbone de cycles aromatiques à six chaînons du même squelette carboné avec des groupes amino et carboxyle liés à des atomes de carbone du même cycle aromatique à six chaînons non condensé le squelette carboné étant substitué de plus par des atomes d'oxygène liés par des liaisons simples
• C07C 227/42 - Cristallisation

Abrégé

A salfaprodil freeze-dried powder injection, and a preparation method therefor and the use thereof. The preparation method of the present invention comprises the following steps: adding salfaprodil into water for injection, carrying out filtration after the salfaprodil is completely dissolved, adjusting the pH value of the filtrate with an aqueous alkaline substance, adding the injection water to realize a constant volume, filling with an inert gas for protection, and carrying out sterilization and filtration to obtain a salfaprodil solution, which is then freeze-dried to obtain the salfaprodil freeze-dried powder injection.

Classes IPC  ?

• A61K 9/19 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres lyophilisées
• A61K 31/196 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino le groupe amino étant lié directement à un cycle, p. ex. acide anthranilique, acide méfénamique, diclofénac, chlorambucil
• A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux

Abrégé

The present invention relates to an ophthalmic liquid composition comprising: a therapeutically effective amount of aflibercept; a buffer containing sodium acetate or histidine; a sugar including sucrose, trehalose, or a combination thereof; and a surfactant that is polysorbate or poloxamer, and a composition for stabilizing aflibercept. The ophthalmic liquid composition of the present invention is characterized by the excellent effect of imparting stability against stresses upon stirring, repeated freezing and thawing, ultraviolet (UV) exposure, and storage at high temperature.

Classes IPC  ?

• A61K 9/08 - Solutions
• A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
• A61K 47/02 - Composés inorganiques
• A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
• A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
• A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire

Abrégé

The present invention relates to pharmaceutical compositions and methods for treating ischemic stroke in humans, using a tetrafluorobenzyl derivative of formula (I) or a pharmaceutically acceptable salt thereof conjointly with a thrombolytic drug, endovascular thrombectomy, or both (e.g., endovascular thrombectomy and a thrombolytic drug). Administration of a tetrafluorobenzyl derivative of formula (I) or its pharmaceutically acceptable salt can reduce reperfusion injury and other adverse events in patients conjointly receiving a thrombolytic drug, endovascular thrombectomy, or endovascular thrombectomy with a thrombolytic drug.

Classes IPC  ?

• A61K 31/196 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino le groupe amino étant lié directement à un cycle, p. ex. acide anthranilique, acide méfénamique, diclofénac, chlorambucil
• A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
• C07C 229/64 - Composés contenant des groupes amino et carboxyle liés au même squelette carboné ayant des groupes amino et carboxyle liés à des atomes de carbone de cycles aromatiques à six chaînons du même squelette carboné avec des groupes amino et carboxyle liés à des atomes de carbone du même cycle aromatique à six chaînons non condensé le squelette carboné étant substitué de plus par des atomes d'oxygène liés par des liaisons simples

Abrégé

The present invention relates to pharmaceutical compositions and methods for treating ischemic stroke in humans, using a tetrafluorobenzyl derivative of formula (I) or a pharmaceutically acceptable salt thereof conjointly with a thrombolytic drug, endovascular thrombectomy, or both (e.g., endovascular thrombectomy and a thrombolytic drug). Administration of a tetrafluorobenzyl derivative of formula (I) or its pharmaceutically acceptable salt can reduce reperfusion injury and other adverse events in patients conjointly receiving a thrombolytic drug, endovascular thrombectomy, or endovascular thrombectomy with a thrombolytic drug.

Classes IPC  ?

• A61K 31/196 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino le groupe amino étant lié directement à un cycle, p. ex. acide anthranilique, acide méfénamique, diclofénac, chlorambucil
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 7/02 - Agents antithrombotiquesAnticoagulantsAnti-agrégants plaquettaires
• A61K 38/48 - Hydrolases (3) agissant sur des liaisons peptidiques (3.4)
• A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale

Abrégé

The present invention relates to pharmaceutical compositions and methods for treating ischemic stroke in humans, using a tetrafluorobenzyl derivative of formula (I) or a pharmaceutically acceptable salt thereof conjointly with a thrombolytic drug, endovascular thrombectomy, or both (e.g., endovascular thrombectomy and a thrombolytic drug). Administration of a tetrafluorobenzyl derivative of formula (I) or its pharmaceutically acceptable salt can reduce reperfusion injury and other adverse events in patients conjointly receiving a thrombolytic drug, endovascular thrombectomy, or endovascular thrombectomy with a thrombolytic drug.

Classes IPC  ?

• A61K 31/196 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino le groupe amino étant lié directement à un cycle, p. ex. acide anthranilique, acide méfénamique, diclofénac, chlorambucil
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
• C07C 229/64 - Composés contenant des groupes amino et carboxyle liés au même squelette carboné ayant des groupes amino et carboxyle liés à des atomes de carbone de cycles aromatiques à six chaînons du même squelette carboné avec des groupes amino et carboxyle liés à des atomes de carbone du même cycle aromatique à six chaînons non condensé le squelette carboné étant substitué de plus par des atomes d'oxygène liés par des liaisons simples

Produits et services

Pharmaceutical preparations for the treatment of multiple sclerosis; pharmaceutical preparations for animals; pharmaceutical products for the treatment of viral diseases; pharmaceutical preparations and substances with anti-inflammatory properties; pharmaceutical preparations for veterinary use; pharmacological preparations for skin care; pharmaceutical preparations for the treatment of cardiovascular disease; chemico-pharmaceutical preparations; pharmaceutical preparations for the treatment of inflammatory diseases; medicated hair care preparations; medicated hair care preparations; medicines for human purposes; pharmaceutical preparations acting on the central nervous system; ethical medicinal preparations; pharmaceutical preparations for the treatment; pain relief medication; burn relief medications; preparations for the treatment of burns. Drug discovery services; conducting clinical trials in the field of cardiovascular disease; development of pharmaceutical preparations and medicines; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; clinical testing of medicines; scientific research in the field of pharmacy; medicine research; providing information on the testing/inspection/research of medical products; medical and pharmacological research services; clinical trials; testing, inspection and research services in the fields of pharmaceuticals, cosmetics and foodstuffs; cosmetics research; cosmetics development services; technological services and research relating thereto; remote monitoring services for medical diagnostic devices [remote monitoring of medical diagnostic systems]; research and development of medical equipment. Preparation and dispensing of medications; medical and health care clinic services; rental of equipment for medical purposes; medical diagnostic services; medical analysis relating to clinical data; advisory services relating to the treatment of degenerative diseases.

Abrégé

A polypeptide capable of binding to SFTSV, comprising 3 complementarity determining regions (CDRs) 1-3, the CDR1 sequence being or comprising one of the sequences shown in SEQ ID NOs: 1-74, the CDR2 sequence being or comprising one of the sequences shown in SEQ ID NOs: 75-151, and the CDR3 sequence being or comprising one of the sequences shown in SEQ ID NOs: 152-232. By means of the preparation of GN protein, immunization of a two-humped camel, and the use of phage library display platform technology for nano-monoclonal antibodies, etc., nano-antibody VHH that specifically binds to GN is screened, CDR sequence thereof is identified, and humanized antibody SNB is constructed; in addition, a humanized mouse model is used to evaluate the efficacy of SNB in the treatment of SFTSV infection. The present solution provides potential novel nano-antibody drugs for the clinical treatment of SFTS, and provides corresponding detection kits for the diagnosis of SFTS.

Classes IPC  ?

• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
• C12N 15/13 - Immunoglobulines
• G01N 33/571 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus pour maladies vénériennes, p. ex. syphilis, gonorrhée, herpès

Abrégé

The present invention relates to a composition comprising: a 5-benzylaminosalicylic acid compound in chemical formula I or cosmetically acceptable salts thereof; and a cosmetically acceptable excipient suitable for local administration. The composition comprising the 5-benzylaminosalicylic acid compound in chemical formula I or cosmetically acceptable salts thereof can be used for reducing or alleviating human skin aging by means of antioxidant, anti-inflammatory and whitening actions on the skin.

Classes IPC  ?

• A61K 8/41 - Amines
• A61K 8/67 - Vitamines
• A61K 8/9789 - Magnoliopsida [dicotylédones]
• A61Q 19/00 - Préparations pour les soins de la peau
• A61Q 19/02 - Préparations pour les soins de la peau pour décolorer ou blanchir la peau chimiquement
• A61Q 19/08 - Préparations contre le vieillissement

Produits et services

Veterinary preparations; medicine cases, portable, filled; food for babies; lactose for pharmaceutical purposes; nutritional supplements; pharmaceuticals; food supplements; dietary supplements; nutraceuticals for use as dietary supplements; nutraceutical preparations for therapeutic or medical purposes; medicated plasters; deodorants, other than for human beings or for animals; bacterial preparations for medical and veterinary use; sanitary pads; adhesives for dentures; diapers for incontinence; diapers for pets; babies' diapers; fly glue; mothproofing paper.

Produits et services

Veterinary preparations for treatment of brain disease, degenerative brain disease, dementia and cognitive dysfunction syndrome; portable medicine cases, filled, namely, portable first-aid boxes, filled; food for babies; lactose for medical purposes; nutritional supplements; pharmaceuticals for the treatment of brain disease, degenerative brain disease, dementia and cognitive dysfunction syndrome; food supplements; dietary supplements; nutraceuticals for use as dietary supplements; nutraceutical preparations for the treatment of brain disease, degenerative brain disease, dementia and cognitive dysfunction syndrome; Plasters for medical purposes; deodorants, other than for human beings or for animals, namely, room deodorants, deodorants for refrigerators, deodorants for clothing, deodorants for textiles, air deodorant; bacterial preparations for medical and veterinary use; sanitary pads; adhesives for dentures; diapers for incontinence; diapers for pets; babies' diapers; fly glue; mothproofing paper

Produits et services

(1) Veterinary preparations for treatment of brain disease, degenerative brain disease, dementia and cognitive dysfunction syndrome; food for babies; lactose for pharmaceutical purposes; nutritional supplements for treatment of brain disease, degenerative brain disease, dementia and cognitive dysfunction syndrome; pharmaceuticals for treatment of brain disease, degenerative brain disease, dementia and cognitive dysfunction syndrome; mineral food supplements; vitamin food supplements; mineral dietary supplements; vitamin dietary supplements; nutraceuticals for use as dietary supplements for treatment of brain disease, degenerative brain disease, dementia and cognitive dysfunction syndrome; nutraceutical preparations for treatment of brain disease, degenerative brain disease, dementia and cognitive dysfunction syndrome; room deodorants; deodorants for refrigerator; deodorants for clothing; deodorants for textiles; air deodorants; sanitary pads; adhesives for dentures; diapers for incontinence; diapers for pets; babies' diapers; fly glue; mothproofing paper.

Abrégé

The present invention relates to an antibody specifically bound to a coagulation factor VIII or an antigen binding fragment thereof, and a use thereof. More specifically, the present invention relates to: an antibody which is specifically bound to a coagulation factor VIII including specific sequences of heavy chain CDR and light chain CDR, or an antigen binding fragment thereof; a column in which the antibody or the antigen binding fragment thereof is coupled to a column stationary phase as a ligand for isolating or purifying a recombinant coagulation factor VIII; and a method for purifying a recombinant coagulation factor VIII using the same.

Classes IPC  ?

• C07K 16/36 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des facteurs de coagulation sanguine
• C07K 1/16 - ExtractionSéparationPurification par chromatographie
• C07K 14/755 - Facteurs VIII

Abrégé

The present disclosure relates to pharmaceutical compositions for treating cognitive decline in companion animals, comprising a 5-benzylaminosalicylic acid compound of formula (I), or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient, e.g., suitable for oral administration. Compositions comprising the 5-benzylamino salicylic acid compound of formula (I), or a pharmaceutically acceptable salt thereof can be used to treat progressive cognitive disorder in neurological diseases including cognitive dysfunction syndrome (CDS), dysthymia, involutive depression, and confusional syndrome in aging companion animals.

Classes IPC  ?

• A61K 31/196 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino le groupe amino étant lié directement à un cycle, p. ex. acide anthranilique, acide méfénamique, diclofénac, chlorambucil
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
• A61K 47/20 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant du soufre, p. ex. sulfoxyde de diméthyle [DMSO], docusate, laurylsulfate de sodium ou acides aminosulfoniques
• A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
• A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
• A61K 47/38 - CelluloseSes dérivés
• A61K 47/42 - ProtéinesPolypeptidesLeurs produits de dégradationLeurs dérivés p. ex. albumine, gélatine ou zéine
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence

Abrégé

The present disclosure relates to pharmaceutical compositions for treating cognitive decline in companion animals, comprising a 5-benzylaminosalicylic acid compound of formula (I), or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient, e.g., suitable for oral administration. Compositions comprising the 5-benzylamino salicylic acid compound of formula (I), or a pharmaceutically acceptable salt thereof can be used to treat progressive cognitive disorder in neurological diseases including cognitive dysfunction syndrome (CDS), dysthymia, involutive depression, and confusional syndrome in aging companion animals.

Classes IPC  ?

• A61K 31/196 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino le groupe amino étant lié directement à un cycle, p. ex. acide anthranilique, acide méfénamique, diclofénac, chlorambucil
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
• A61K 47/38 - CelluloseSes dérivés
• A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
• A61K 47/20 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant du soufre, p. ex. sulfoxyde de diméthyle [DMSO], docusate, laurylsulfate de sodium ou acides aminosulfoniques
• A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
• A61K 47/42 - ProtéinesPolypeptidesLeurs produits de dégradationLeurs dérivés p. ex. albumine, gélatine ou zéine
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence

Abrégé

The present invention provides an antibody having cross-linking ability against human Sema3A and mouse Sema3A. The antibody of the present invention can be used as therapeutic antibody drugs for inhibiting Sema3A in various cancers in which Sema3A expression is high, such as glioblastoma, pancreatic cancer and liver cancer. Since Sema3A is considered to be a therapeutic target of diabetic retinopathy, autoimmune arthritis, neuropathic pain and osteoporosis, the antibody of the present invention or an antigen binding fragment thereof can be used as a therapeutic agent for associated diseases in addition to an anti-cancer drug. The antibody of the present invention inhibits the growth of cancer cells derived from various carcinomas through inhibition of Sema3A function due to high anti-Sema3A binding, and inhibits the movement of cancer cells through inhibition of phosphorylation of ERK among Sema3A lower signaling substances.

Classes IPC  ?

• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• A61P 35/00 - Agents anticancéreux
• A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

The present invention provides an antibody having cross-linking ability against human Sema3A and mouse Sema3A. The antibody of the present invention can be used as therapeutic antibody drugs for inhibiting Sema3A in various cancers in which Sema3A expression is high, such as glioblastoma, pancreatic cancer and liver cancer. Since Sema3A is considered to be a therapeutic target of diabetic retinopathy, autoimmune arthritis, neuropathic pain and osteoporosis, the antibody of the present invention or an antigen binding fragment thereof can be used as a therapeutic agent for associated diseases in addition to an anti-cancer drug. The antibody of the present invention inhibits the growth of cancer cells derived from various carcinomas through inhibition of Sema3A function due to high anti-Sema3A binding, and inhibits the movement of cancer cells through inhibition of phosphorylation of ERK among Sema3A lower signaling substances.

Classes IPC  ?

• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• A61P 35/00 - Agents anticancéreux
• A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

The present invention provides an antibody having cross-linking ability against human Sema3A and mouse Sema3A. The antibody of the present invention can be used as therapeutic antibody drugs for inhibiting Sema3A in various cancers in which Sema3A expression is high, such as glioblastoma, pancreatic cancer and liver cancer. Since Sema3A is considered to be a therapeutic target of diabetic retinopathy, autoimmune arthritis, neuropathic pain and osteoporosis, the antibody of the present invention or an antigen binding fragment thereof can be used as a therapeutic agent for associated diseases in addition to an anti-cancer drug. The antibody of the present invention inhibits the growth of cancer cells derived from various carcinomas through inhibition of Sema3A function due to high anti-Sema3A binding, and inhibits the movement of cancer cells through inhibition of phosphorylation of ERK among Sema3A lower signaling substances.

Classes IPC  ?

• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• C12N 15/70 - Vecteurs ou systèmes d'expression spécialement adaptés à E. coli
• A61P 35/00 - Agents anticancéreux
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire

Abrégé

The present invention relates to an antibody specifically bound to a hemocoagulation factor VIII or an antigen binding fragment thereof, and a use thereof. More specifically, the present invention relates to: an antibody which is specifically bound to a hemocoagulation factor VIII including specific sequences of heavy chain CDR and light chain CDR, or an antigen binding fragment thereof; a column in which the antibody or the antigen binding fragment thereof is coupled to a column stationary phase as a ligand for isolating or purifying a recombinant hemocoagulation factor VIII; and a method for purifying a recombinant hemocoagulation factor VIII using the same.

Classes IPC  ?

• C07K 16/36 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des facteurs de coagulation sanguine
• C07K 1/16 - ExtractionSéparationPurification par chromatographie
• C07K 14/755 - Facteurs VIII
• B01D 15/38 - Adsorption sélective, p. ex. chromatographie caractérisée par le mécanisme de séparation impliquant une interaction spécifique non couverte par un ou plusieurs des groupes , p. ex. chromatographie d'affinité, chromatographie d'échange par ligand ou chromatographie chirale

Abrégé

The present invention provides an antibody having the ability to be cross-linked to human Sema3A and mouse Sema3A. The antibody of the present invention can be used as a therapeutic antibody for inhibiting Sema3A in various carcinomas in which Sema3A expression is high, such as glioblastoma, pancreatic cancer and liver cancer. Since Sema3A is considered to be a therapeutic target of diabetic retinopathy, autoimmune arthritis, neuropathic pain and osteoporosis, the antibody of the present invention or an antigen binding fragment thereof can be used as an agent, in addition to being used as an anticancer drug, for treating associated diseases. The antibody of the present invention inhibits the growth of cancer cells derived from various carcinomas, by using high anti-Sema3A binding and Sema3A function inhibition caused thereby, and inhibits the migration of cancer cells by inhibiting the phosphorylation of ERK among the downstream signaling materials of Sema3A, thereby being very effective in cancer prevention and treatment.

Classes IPC  ?

• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire

Abrégé

There is provided an expression vector for animal cell having an increased gene expression efficiency, and particularly, an expression vector for animal cells including a MAR element and a SAR element, which are gene expression increasing factors, at a 5′ end of a promoter, a 3′ end of a transcription termination site, or at both of the 5′ end of the promoter and the 3′ end of the transcription termination site. The expression vector for animal cells according to the present invention exhibits remarkably increased gene expression efficiency as compared to conventional expression vectors for animal cells, such that protein expression of foreign genes may be significantly increased using this expression vector for animal cells. Particularly, the expression vector for animal cells according to the present invention may be useful in that a high-expression cell line may be secured even without MTX amplification.

Classes IPC  ?

• C12N 15/00 - Techniques de mutation ou génie génétiqueADN ou ARN concernant le génie génétique, vecteurs, p. ex. plasmides, ou leur isolement, leur préparation ou leur purificationUtilisation d'hôtes pour ceux-ci
• C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• C12P 21/02 - Préparation de peptides ou de protéines comportant une séquence connue de plusieurs amino-acides, p. ex. glutathion
• C07H 21/00 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques
• C07H 19/06 - Radicaux pyrimidine
• C07H 19/16 - Radicaux purine
• C12N 5/02 - Propagation de cellules individuelles ou de cellules en suspensionLeur conservationMilieux de culture à cet effet
• C12N 5/07 - Cellules animales ou tissus animaux
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
• C12P 21/06 - Préparation de peptides ou de protéines préparés par hydrolyse d'une liaison peptidique, p. ex. hydrolysats

Abrégé

The present invention relates to an expression vector intended for animal cells and having increased gene-expression capacity. More particularly, the present invention relates to an expression vector for animal cells, which comprises MAR factor and SAR factor, which are factors for increasing gene expression, at the 5' end of a promoter or the 3' end of a transcription termination factor, or at both the 5' end of the promoter and the 3' end of the transcription termination factor. The expression vector for animal cells according to the present invention exhibits remarkably increased gene-expression capacity as compared to conventional expression vectors for animal cells, and therefore may significantly increase the protein expression of exotic genes. Specifically, the expression vector for animal cells according to the present invention enables a high-expression cell line to be ensured even without MTX amplification, and is therefore very useful.

Classes IPC  ?

• C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
• C12N 15/12 - Gènes codant pour des protéines animales
• C12N 1/21 - BactériesLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus

Abrégé

The present invention relates to new medical uses for ethylamino benzoic acid derivatives or pharmaceutically acceptable salts thereof.

Classes IPC  ?

• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61K 31/136 - Amines, p. ex. amantadine ayant des cycles aromatiques, p. ex. méthadone ayant le groupe amino lié directement au cycle aromatique, p. ex. benzène-amine
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]

Abrégé

The present invention relates to a pharmaceutical composition useful for treating or preventing inflammatory disease and cell damage, and a method for treating or preventing inflammatory disease and cell damage. The present invention uses the 2-hydroxybenzoic acid derivative represented by the specific chemical formula or its pharmaceutically acceptable salt. The compound of the present invention is useful for treating or preventing cell damage and inflammatory disease including gastritis, gastric ulcer, pancreatitis, colitis, arthritis, diabetes, arteriosclerosis, nephritis, hepatitis, Alzheimer's disease, Parkinson's disease and Lou Gehrig's disease.

Classes IPC  ?

• A61K 31/33 - Composés hétérocycliques

Abrégé

Disclosed is a method for inhibition of necrosis induced by neurotrophin, and more specifically a method for inhibition of necrosis by administrating oxidative stress inhibitor and a method for simultaneous inhibition of necrosis and apoptosis by administrating oxidative stress inhibitor and neurotrophin. The oxidative stress inhibitor of the present invention can inhibit nerve cell necrosis induced by neurotrophin. Moreover, it can be used for protecting nerve cell damage connected with alzheimer disease, parkinson's disease, degenerating cerebropathia and promoting regeneration of the nerve cells by administrating oxidative stress inhibitor and neurotrophin.

Classes IPC  ?

• A61K 38/18 - Facteurs de croissanceRégulateurs de croissance
• C07C 229/68 - Composés contenant des groupes amino et carboxyle liés au même squelette carboné ayant des groupes amino et carboxyle liés à des atomes de carbone de cycles aromatiques à six chaînons du même squelette carboné avec des groupes amino et carboxyle liés à des atomes de carbone de cycles aromatiques à six chaînons faisant partie du même système cyclique condensé
• C07K 14/475 - Facteurs de croissanceRégulateurs de croissance